Genomic Valley Biotech Ltd - 539206 - Board Meeting Outcome for Outcomes Of Board Meeting And Audited Financial Results (Standalone) For The Quarter And Year Ended 31St March, 2023
Outcomes of Board Meeting and Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2023 Genomic Valley Biotech Ltd - 539206 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the Financial Year 2022-23 under Regulation 24A of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements published for the Notice of Board Meeting to be held on 29th May, 2023, inter-alia, to consider and approve the Audited Financial Results for the quarter and year ended 31st March, 2023, in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 24th May, 2023 Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
Closure of Trading Window Genomic Valley Biotech Ltd - 539206 - Board Meeting Intimation for Considering And Approving Audited Financial Results For The Quarter And Year Ended March 31, 2023
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 ,inter alia, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2023 Genomic Valley Biotech Ltd - 539206 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Genomic Valley Biotech Ltd 2 CIN NO. L01122HR1994PLC033029 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) NIL 8Quantum of (d), which has been met from (c)(e)* NIL 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NIL Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Anupam AdityaDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- NIL Designation : -Chief Financial Officer Date: 26/04/2023 Genomic Valley Biotech Ltd - 539206 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGenomic Valley Biotech Ltd 2CIN NO.L01122HR1994PLC033029 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NIL 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Anupam Aditya Designation: Company Secretary and Compliance Officer EmailId: genomicvalley@gmail.com Name of the Chief Financial Officer: NIL Designation: Chief Financial Officer EmailId: genomicvalley@gmail.com Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Genomic Valley Biotech Ltd - 539206 - Certificate Pursuant To Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Certificate pursuant to Regulation 40 (10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Genomic Valley Biotech Ltd - 539206 - Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On 31St March, 2023
Compliance Certificate pursuant to Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on 31st March, 2023